Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-004650-34-IT (EUCTR)	27/06/2016	05/11/2020	New strategies for diagnostic, therapeutic and clinical care in neurological diseases	Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia - New strategies in neurological diseases	Multiple sclerosis with cerebellar ataxia MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) INN or Proposed INN: FAMPRIDINA Other descriptive name: 4-aminopyridine	IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 4	Italy
2	EUCTR2013-002558-64-IT (EUCTR)	18/12/2013	16/10/2013	improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis	A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis.	MULTIPLE SCLEROSIS MedDRA version: 20.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: fampyra Product Name: FAMPYRA INN or Proposed INN: FAMPRIDINE	dipartimento di neurologia e psichiatria	NULL	Not Recruiting			Female: yes Male: yes	123	Phase 4	Italy